Drug profile · INN
plicamycin
MITHRACIN
plicamycin (MITHRACIN) is a dna inhibitor. Route of administration: injection. Current US regulatory status: approved.
FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — plicamycin
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
plicamycin (MITHRACIN) is a dna inhibitor. Route of administration: injection. Current US regulatory status: approved.
Key facts
INN plicamycin
Brand MITHRACIN
Mechanism DNA inhibitor
Target DNA
Route INJECTION
Formulation INJECTABLE
Mechanism of action
DNA inhibitor
Primary target: DNA
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is plicamycin?
plicamycin (MITHRACIN) is a dna inhibitor. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for plicamycin?
MITHRACIN is a marketed brand name for plicamycin. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of plicamycin?
plicamycin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.